2018
DOI: 10.1038/s41418-018-0196-2
|View full text |Cite
|
Sign up to set email alerts
|

Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids

Abstract: Current clinical diagnosis is typically based on a combination of approaches including clinical examination of the patient, clinical experience, physiologic and/or genetic parameters, high-tech diagnostic medical imaging, and an extended list of laboratory values mostly determined in biofluids such as blood and urine. One could consider this as precision medicine v1.0. However, recent advances in technology and better understanding of molecular mechanisms underlying disease will allow us to better characterize… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 177 publications
(130 reference statements)
0
12
0
Order By: Relevance
“…The results of this study suggest cell death inhibitors or suppressors of inflammation to be tested in future studies. Thereby this study serves as early step to help pave the way for a delayed, phase dependent and precise therapy of ATN to avoid transition to CKD [50].…”
Section: Discussionmentioning
confidence: 99%
“…The results of this study suggest cell death inhibitors or suppressors of inflammation to be tested in future studies. Thereby this study serves as early step to help pave the way for a delayed, phase dependent and precise therapy of ATN to avoid transition to CKD [50].…”
Section: Discussionmentioning
confidence: 99%
“…In the last decade, many different treatment approaches were approved based on specific genetic characteristics such as anti-EGFR directed therapies in patients with RAS wild-type colorectal cancer [7]. Thus, providing individualized or personalized medicine requires the availability of specific “biomarkers” that allow stratification of patients into different subgroups [8]. The National Institutes of Health (NIH) define a biomarker as “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence or outcome of disease” or, more broadly, as “almost any measurement reflecting an interaction between a biological system and a potential hazard, which may be chemical, physical, or biological.…”
Section: Introductionmentioning
confidence: 99%
“…Further consideration of the probesets narrowed down the number of potential cytokines for modelling to 14, each of which has data available for both receptors and cytokine (about 30 probesets) : IL1A, IL1B, IL2, IL3, IL4, IL6, IL10, IL11, IL12A, IL13, IL16, IL18, IL24 and IL27. Of these, IL1, IL4, IL6, IL10, IL18 have been strongly associated with sepsis [7,[34][35][36][37][38][39][40], with 1L1, IL6 and IL18 being proinflammatory and IL4 and IL10 anti-inflammatory. From this set of 5 cytokines, IL18/IL10 was identified as the optimal pair for modelling.…”
Section: Biological Selection Of the Probesetsmentioning
confidence: 99%